U.S. equities closed the second quarter of 2026 at or near record highs on Tuesday, June 30, powered by a massive AI‑chip melt‑up, resilient consumer spending, and investors’ willingness to look through macro cross‑currents into 2H26 earnings and rate‑cut potential.
Headline Takeaways – Q2 Ends With AI-Fueled Surge
- The Dow Jones Industrial Average climbed to a fresh all‑time high into quarter‑end, underscoring rotation into quality cyclicals alongside megacap tech.
- The S&P 500 delivered its strongest quarter since 2020, rising roughly mid‑teens percent, while the Nasdaq Composite rallied north of 20% as AI and semiconductor names led performance.
- Market breadth improved in late June, with communication services, consumer discretionary, and information technology all outperforming, while defensives lagged.
Today’s tape reinforced the idea that Q2 2026 was less about “higher for longer” rates and more about “earnings plus AI leverage,” with equity multiples expanding on the back of AI‑infrastructure and AI‑application themes.
Macro Backdrop – Late-Cycle Feel, Early-AI Exuberance
- U.S. stocks rallied as geopolitical tension between the United States and Iran showed signs of easing, helping risk appetite and pressuring oil, which remains far below war‑time peaks.
- The Japanese yen hovered near a 40‑year low, keeping FX intervention chatter alive and offering a tailwind to exporters but a headwind for imported inflation.
- June itself was choppy, with the S&P 500 drifting near flat for the month at times, but the quarter’s performance remained robust as investors bought dips in tech and AI‑exposed names.
Under President Donald Trump’s administration, the policy mix of tax cuts, tariff recalibration, and pressure on energy producers continues to intersect with AI capex and reshoring narratives, creating an environment where earnings and productivity stories can offset macro uncertainty in inflation and geopolitics.
Sector & Thematic Moves – AI Chips, Cloud, and Healthcare
AI Semiconductor Supercycle
- An AI‑chip rally across the quarter added roughly $2 trillion in market value to leading U.S. semiconductor players, including Micron Technology (MU), Intel (INTC), and Advanced Micro Devices (AMD).
- Applied Materials (AMAT) surged double digits recently as investors leaned into semi‑equipment leverage to AI‑driven foundry and memory spending.
- Alphabet (GOOGL), newly in the Dow, jumped sharply as investors rewarded its AI‑enabled ad, cloud, and productivity stack.
This now sets up Q3 as a “proof quarter” for AI‑hardware and AI‑infrastructure: investors will look for MU, INTC, AMD, and AMAT to convert backlog and design wins into durable margin expansion, not just AI‑hype beta.
Cloud & Enterprise AI – AWS Steps Forward
- Amazon.com’s cloud arm, Amazon Web Services (AWS), announced a $1 billion commitment to a new Forward Deployed Engineering (FDE) unit, embedding thousands of engineers directly with customers to accelerate AI adoption.
- Initial AWS FDE customers include the National Basketball Association, Ricoh, and the National Football League, highlighting a cross‑industry push to operationalize AI agents and production‑grade models.
This move positions Amazon (AMZN) to deepen wallet share in AI transformation budgets, while also signaling that “AI services plus embedded engineers” may become a standard competitive offering across hyperscalers.
AI + Drug Discovery – Anthropic Joins the Hunt
- Anthropic, structured as a public benefit company, launched an internal drug discovery program to complement its Claude Science platform, focused on “neglected” diseases that traditional biopharma often overlooks.
- Management presented the initiative as a dual mandate: build AI tools for life sciences partners while directly pursuing patient‑centric programs that commercial markets may under‑prioritize.
This announcement is directionally important for biotech investors: it underscores the growing convergence of foundation models and drug discovery workflows, putting companies aligned with AI‑native target ID, molecule design, and trial optimization squarely in the Q3 spotlight.
Nike (NKE) – Q4 2026 Earnings Snapshot
- Nike (NKE) reported fiscal Q4 2026 earnings today, offering a lens into global consumer demand, inventory discipline, and DTC versus wholesale channel dynamics. They highlighted:
- Full year revenues were $46.4 billion, flat on a reported basis and down 2 percent on a currency-neutral basis*
- Fourth quarter revenues were $11.0 billion, down 1 percent on a reported basis and down 4 percent on a currency-neutral basis
- Wholesale revenues for the fourth quarter were $6.6 billion, up 4 percent on a reported basis and up 1 percent on a currency-neutral basis
- NIKE Direct revenues for the fourth quarter were $4.1 billion, down 7 percent on a reported basis and down 9 percent on a currency-neutral basis
Index & Sector Performance – End of Quarter Snapshot
| Index / Sector | Move in Q2 2026 | Narrative Hook |
|---|---|---|
| Dow Jones Industrial Average (DJIA) | Record high; strong quarter close at 52,319.20 | Quality cyclicals and megacap tech co‑leading. |
| S&P 500 (SPX) | ~15% quarterly gain, best since 2020, closing at 7,499.36. | AI, consumer, and comms services drive multiple expansion. |
| Nasdaq Composite (IXIC) | ~21% quarterly gain, closing at 26,213.72. | AI chips and software lead, tech volatility faded into strength. |
| Information Technology (XLK) | ~1.7% gain in latest session. | Semi and AI infrastructure at the core of Q2 leadership. |
| Communication Services (XLC) | ~3.1% daily jump. | Alphabet and peers repriced on AI monetization. |
| Consumer Discretionary (XLY) | ~2.7% gain. | Nike and other brands watched as rate path and jobs remain key. |
These moves collectively reinforce a “risk‑on but selective” Q2 backdrop, where investors favor cash‑generative, AI‑levered platforms and high‑quality cyclicals over defensives and rate‑sensitives.
What’s Next – Set‑Up for Q3 2026
- Macro: Markets will trade on incoming inflation prints, labor data, and central‑bank signaling around the timing and magnitude of potential rate cuts into late 2026.
- Earnings: The bar is higher for AI‑beneficiaries; investors will demand evidence that MU, INTC, AMD, AMAT, AMZN, GOOGL, and peers can sustain high‑teens‑plus growth and margin resilience beyond Q2’s AI‑rally.
- Thematics: Expect continued interest in AI‑drug discovery (Anthropic and biopharma partners), cloud‑delivered AI services (AWS, Alphabet, Microsoft (MSFT)), and transition‑energy plays such as FCEL as capital chases productivity and decarbonization simultaneously.
VP Watchlist Updates
Amwell® (NYSE: AMWL)
Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $9.12.
Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX, $6.61, +.30%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”
Modular Medical, Inc. (NASDAQ: MODD)
Modular Medical, Inc. (NASDAQ: MODD, $4.50), a leader in innovative, patient-centric insulin delivery, today (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.
MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.
MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”
On (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.
Similarweb Ltd. (NYSE: SMWB)
Similarweb Ltd. (NYSE: SMWB, $6.13), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.
NVIDIA (NVDA)
NVIDIA (NVDA) closes at $200.09, +2.63%.
Rocket Lab Corporation (Nasdaq: RKLB)
Rocket Lab Corporation (Nasdaq: RKLB, $97.95, +15.86%), a global leader in launch and space systems and Iridium Communications Inc. (Nasdaq: IRDM, $54.85, +24.21% over the last 5-days) a leading provider of global voice, data, and positioning, navigation, and timing (PNT) satellite services, announced (June 29) they have entered into a definitive agreement under which Rocket Lab will acquire Iridium. Rocket Lab will acquire all the outstanding shares of Iridium common stock for $54 per share in a cash and stock transaction. This represents an enterprise value for Iridium of approximately $8.0 billion.
The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $48.92, +5.75%.
FuelCell Energy (FCEL) – Clean Power Capital
- FuelCell Energy (FCEL, $36.01, +20.84% on Tuesday) secured approximately $49 million in funding, strengthening its balance sheet to support ongoing fuel‑cell and hydrogen‑related project development.
- The raise reinforces investor interest in transition‑energy infrastructure even as large‑cap AI and tech dominate the tape, giving FCEL incremental runway to pursue utility and industrial deployments.
The Sources
- Yahoo Finance – “Dow hits record, S&P 500 jumps to cap best quarter since 2020 amid massive chip rally”
https://finance.yahoo.com/markets/live/stock-market-today-dow-hits-record-sp-500-jumps-to-cap-best-quarter-since-2020-amid-massive-chip-rally-224823556.html - CNBC – “Stock market today: Live updates” (June 29, 2026)
https://www.cnbc.com/2026/06/29/stock-market-today-live-updates.html - CNBC – “Nike (NKE) Q4 2026 earnings”
https://www.cnbc.com/2026/06/30/nike-nke-q4-2026-earnings.html - CNBC – “AI chip rally in Q2 adds $2 trillion in value to Micron, Intel, AMD…”
https://www.cnbc.com/2026/06/30/ai-chip-rally-in-q2-adds-2-trillion-in-value-to-micron-intel-amd-.html - CNBC – “Anthropic launches AI drug discovery program – Claude Science”
https://www.cnbc.com/2026/06/30/anthropic-launches-ai-drug-discovery-program-claude-science.html - CNBC – “AWS Amazon AI forward deployed engineers” / Reuters AWS coverage
https://www.cnbc.com/2026/06/30/aws-amazon-ai-forward-deployed-engineers.html - Yahoo Finance – “FuelCell Energy secures $49 million”
https://finance.yahoo.com/energy/articles/fuelcell-energy-secures-49-million-113000463.html
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
